Protocol for Radiofrequency Ablation of Pulmonary Neoplasms

Pulmonary Neoplasms Clinical Trial

Official title:

Protocol for Radiofrequency Ablation of Pulmonary Neoplasms

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00232128
• Other study ID #: CCI LUN 02
• Status: Terminated
• Phase: N/A
• First received: October 3, 2005
• Last updated: January 11, 2007
• Start date: June 2003

Study information

• Verified date: May 2006
• Source: Oncology Specialties, Alabama
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This research trial involves the development of a new treatment for lung tumors. It is for patients whose tumor cannot be surgically removed, have refused surgery, or the tumor has not responded well to other forms of treatment. This treatment uses a needle probe to deliver energy into the lung tumor. This probe is placed utilizing a CT scan image. The energy heats the tumor causing tumor cell death.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 0
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 19 Years and older

Eligibility

Inclusion Criteria: The patients enrolled in this study should be judged to have sufficient survival to benefit from control of local disease and include at least one of the following:

1. unresectable primary or metastatic lung tumors

2. may benefit from multiple modalities of therapy

3. chemotherapeutic or radiation oncologic options have been exhausted

Exclusion Criteria:

1. co-existing morbidities that preclude the use of surgery

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lung Neoplasms
• Neoplasms
• Pulmonary Neoplasms

Intervention

Procedure:
• Radiofrequency Ablation of pulmonary neoplasms

Locations

Country	Name	City	State
United States	Comprehensive Cancer Institute	Huntsville	Alabama

Sponsors (1)

Lead Sponsor	Collaborator
Oncology Specialties, Alabama

Country where clinical trial is conducted

United States,